Jazz Pharmaceuticals plc
NASDAQ:JAZZ
| Market Cap (Intraday) | 6.83B |
| Current PE | 14.16 |
| Forward PE | 23.61 |
| 2yr Forward PE | 5.24 |
| 10-Day MA | $112.25 |
| 50-Day MA | $108.56 |
| 200-Day MA | $118.32 |
Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ
Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800
Description
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.